GLP-1s Don't Make You Move More
We hear a version of the same hopeful theory from a lot of new GLP-1 patients: once the weight starts coming off, they'll finally have the energy to get back to the gym. New wearable-device data presented at this year's Endocrine Society annual meeting says the opposite tends to happen — and it's a bigger deal than it sounds.
The short version
Why this study is different from the usual GLP-1 headline
Most of what circulates about GLP-1 drugs is about the scale: how many pounds, how fast, compared with what. This study, led by Dr. Sajana Maharjan and presented at ENDO 2026, looked at something nobody was formally tracking — what actually happens to how much people move once they start the medication. Instead of relying on self-reported exercise logs, which are notoriously unreliable, the researchers used objective Fitbit data pulled from the All of Us Research Program, a large NIH biobank and research cohort that includes continuous wearable-device records for enrolled participants. That let them compare each person's own step counts and active minutes before and after they started treatment, rather than comparing different groups of people against each other.
The cohort was 753 adults with obesity, averaging 52.7 years old and 78.6% female, with substantial overlapping health burden: 81.9% had musculoskeletal pain, 67.3% had hypertension, and 48.1% had type 2 diabetes. That's a realistic cross-section of who actually gets prescribed a GLP-1 in practice, not a cherry-picked trial population of otherwise-healthy volunteers.
What the wearable data actually showed
The 560-step daily decline (about an 11% drop) was consistent across the group, and moderate-to-vigorous activity minutes fell by roughly a fifth. But the averages hid a sharper split underneath. Men lost more than twice as many steps as women — 986 versus 445 a day — and far more vigorous-activity minutes (15.3 versus 2.9, both differences statistically significant). People already dealing with musculoskeletal pain lost the most ground of all, dropping 679 steps a day compared with just 22 steps among those without pain. Age, heart failure, and a prior stroke didn't meaningfully change the pattern one way or the other.
Why losing weight doesn't automatically mean moving more
The intuitive assumption — lighter body, easier movement, more activity — turns out to be too simple. GLP-1 drugs work partly by suppressing appetite and slowing digestion, which for some patients comes with nausea, fatigue, or reduced spontaneous energy, especially in the first weeks after a dose increase. Significant calorie reduction on its own, independent of any medication, is also a known trigger for the body to conserve energy by reducing non-exercise activity — fidgeting, walking, taking the stairs — a phenomenon researchers call NEAT (non-exercise activity thermogenesis) compensation. On top of that, a meaningful share of GLP-1 patients are losing weight precisely because joint pain or mobility limits made activity difficult before they ever started the drug, and a smaller number on the scale doesn't instantly undo arthritis or chronic pain. None of this means the drugs are doing something wrong. It means the weight loss and the activity level are two separate things that both need to be managed, not one thing that automatically produces the other.
This connects to a problem we've written about before: lean mass loss on GLP-1 therapy, which can run anywhere from roughly a quarter to over 40% of total weight lost depending on the person. Lower daily movement compounds that risk directly — muscle that isn't being used is muscle that's easier to lose, which is exactly the outcome resistance training and activity are supposed to prevent.
Safety and what we tell patients
There's nothing unsafe about the finding itself — lower step counts aren't a medication side effect that needs to be reported — but it is a gap in care that's easy to miss if nobody is looking for it. Dr. Maharjan's team put it plainly: "exercise needs to be actively prescribed alongside GLP-1 therapy, not assumed to follow from weight loss." In practice, that means a few concrete things. Structured exercise counseling at the time treatment starts, not as an afterthought once weight loss has stalled. Targeted resistance training, since preserving muscle is the single best lever patients have against the lean-mass trade-off GLP-1s create. A referral to physical therapy or pain management for anyone whose joint or muscle pain is limiting movement, rather than just waiting for weight loss to eventually help. Simple wearable-device tracking, since this study's whole value came from objective step data rather than self-report. And extra attention for male patients specifically, given how much steeper their decline was in this cohort.
Bottom line
A GLP-1 prescription is not, by itself, an activity plan. The best available data says patients tend to move less after starting one, not more, and the people most likely to need movement — those with existing joint pain — are the ones losing the most of it. If you're on or starting a GLP-1, ask your provider for an activity and resistance-training plan at the same visit where the prescription gets written, not six months later when the scale has already moved and the muscle loss has already happened.
Sources: The Endocrine Society (ENDO 2026 press release, Maharjan et al.); Healio (clinical reporting on study statistics and methodology); NIH All of Us Research Program (wearable-device data source); Mayo Clinic (clinical guidance on exercise and GLP-1 therapy).